# Clinical Trials Data KIT - Document 20

# Molecular Mechanisms and Diagnosis of Mastocytosis

## Clinical Trial: https://clinicaltrials.gov/study/NCT00336076

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Confirmed or suspected diagnosis of mastocytosis.\n\* Ability to give informed consent (by the patient or legal guardian if minor)\n\nExclusion Criteria:\n\n\* Inability or not willing to provide informed consent.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with confirmed or suspected mast cell disease",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
To determine whether a patient with a KIT gene mutation would be eligible for the clinical trial based solely on the information provided, let's consider the key points:  
  
1. \*\*Eligibility Criteria:\*\*  
 - \*\*Inclusion Criteria:\*\*   
 - The patient must have a confirmed or suspected diagnosis of mastocytosis.  
 - The patient must be able to give informed consent (or their legal guardian if they are a minor).  
  
 - \*\*Exclusion Criteria:\*\*  
 - Inability or unwillingness to provide informed consent.  
  
2. \*\*Study Population:\*\*   
 - Patients with confirmed or suspected mast cell disease.  
  
There is no specific mention of a KIT gene mutation affecting eligibility in the criteria provided. The primary eligibility factors focus on the diagnosis of mastocytosis and the ability to provide informed consent.   
  
If the patient with a KIT gene mutation also has a diagnosis of mastocytosis or another form of mast cell disease and can give informed consent, they may be eligible for the trial. However, it's important to verify with the trial organizers to ensure there aren't additional criteria not listed here that could affect eligibility.